IBA – Transparency Notification

 (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)

Louvain-la-Neuve, Belgium, May 28, 2020, 17.30

Summary of the notification

IBA (Ion Beam Application), the world’s leading provider of proton therapy solutions for the treatment of cancer, received a transparency notification dated May 19, 2020, from which it follows that, following the introduction of statutory thresholds on April 30, 2020, the University Catholique de Louvain, including the voting rights of its subsidiary Sopartec SA, now holds 2.71% of the voting rights in the company. It thus crossed upwards the 2% participation threshold.

Content of the notification

• Reason for the notification: Introduction of statutory thresholds
• Notification by : A parent undertaking or a controlling person
• Persons subject to the notification requirement:
  Université Catholique de Louvain (UCLouvain), Place d’l’Université 1, 1348 Louvain-la-Neuve
  Sopartec SA, Place d’l’Université 1, 1348 Louvain-la-Neuve

• Date on which the threshold is crossed: 30/04/2020
• Threshold crossed (in %): 2%
• Denominator: 38 085 047

• Notified details: (extract of the received notification form) 

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
UCLouvain	426.885	853.770	0	2.24%	0.00%
Sopartec SA	403.049	180.000	0	0.47%	0.00%
Subtotal	829.934	1.033.770		2.71%
	TOTAL	1.033.770	0	2.71%	0,00%
B) Equivalent financial instruments	After the transaction
Holder of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
	TOTAL			0	0.00%
	TOTAL (A & B)			# of voting rights	%of voting rights
				1.033.770	2.71%

• Full chain of controlled undertakings through which the holding is effectively held

Sopartec SA is a subsidiary of UCLouvain (100% minus one share).

• Additional Information

Passive crossing following the introduction of the loyalty vote and new thresholds in the Issuer's articles of association.
Reminder of the legal status of UCLouvain: legal person under private law pursuing an aim of public utility and enjoying civil personality under a law of 12 August 1911 modified by a law of 28 May 1970.

For further information, please contact:

IBA

Elodie Jaumain
Paralegal
+32 10 203 180

[email protected]

About IBA

IBA (Ion Beam Applications) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

 

 

Attachment

• 20200528transparencyUCL_SOPARTEC_EN(au-dessus2%)